NCT03038516View on ClinicalTrials.gov

'Palliative-D' Vitamin D to Palliative Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

244

Participants

Timeline

Start Date

November 1, 2017

Primary Completion Date

June 9, 2020

Study Completion Date

June 9, 2020

Conditions
Vitamin D Deficiency
Interventions
DRUG

Cholecalciferol

To test the hypothesis that vitamin D treatment during 12 weeks to palliative cancer patients is superior to placebo in decreasing opioid consumption, fatigue and infectious burden and increase quality of life.

DEVICE

Placebo

To test the hypothesis that placebo is inferior to vitamin D treatment during 12 weeks to palliative cancer patients in decreasing opioid consumption,

Trial Locations (3)

11219

Stockholms Sjukhem ASIH, Stockholm

12559

ASIH Stockholm Södra, Älvsjö

171 54

ASIH Stockholm Norr, Solna

All Listed Sponsors
lead

Region Stockholm

OTHER_GOV

NCT03038516 - 'Palliative-D' Vitamin D to Palliative Cancer Patients | Biotech Hunter | Biotech Hunter